February 22, 2021/Cancer/Radiation Oncology

IMRT for Diffuse Cutaneous Breast Cancer Metastases

Minimizing patient discomfort, improving quality of life

650×450-Breast-Cancer-Skin-Reoccurances

Thanks to advances in screening and treatments, patients with breast cancer are living longer. As a result, diffuse cutaneous metastases are becoming more common, and these skin lesions can severely impact patient quality of life. Cleveland Clinic Cancer Center’s Department of Radiation Oncology has developed techniques that minimize patient discomfort and improve quality of life using streamlined intensity-modulated radiation therapy (IMRT).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“There’s a common myth that once a patient has been treated with radiation for breast cancer, they cannot be treated again, or that the area of skin metastases is too large to treat,” says Chirag Shah, MD, Director of Breast Radiation Oncology at Cleveland Clinic Cancer Center. “We absolutely can use radiation on large, diffuse skin metastases while sparing the heart and lung, which is really important because these cases are not commonly treated with surgical interventions.”

Conventional techniques, such as 3-dimension conformal radiation therapy and electron fields, are difficult to set up and cannot spare normal tissues as well in the re-irradiation setting. With IMRT, patients can receive high doses of radiation that avoid normal tissues and are effective in re-irradiation. Some centers use this approach for diffuse cutaneous metastases, but no published guidelines or preferred methodologies exist.

IMRT techniques

A recent report published in The Breast Journaloffers a methodology that improved quality of life for several patients and is preferred by Cleveland Clinic clinicians for patients presenting with such clinical indications. The report discusses five patients who initially had locally advanced, nonmetastatic breast cancer and a median time to metastatic recurrence of 17 months. Four of five patients had been treated with postmastectomy radiation therapy (PMRT).

Advertisement

Clinical presentation. (A) Right axilla (B) Chest wall (C) Posterior chest wall (D) Posterior chest wall one month after completion of 30 Gy in 10 fractions with near complete response. Figure and caption republished with permission from Wiley.

“Our preferred technique involves mapping areas of disease and then wiring 2 to 3 centimeters beyond that while placing bolus to enhance skin dose. Then we utilize the treatment planning system to turn the wires into a volume to be treated. The patients are lying down, and this takes about an hour,” says Dr. Shah, senior author of the paper.

A dosimetrist working with a computer algorithm turns the map into preliminary radiation targets, which clinicians review and adjust to ensure accuracy. The dosimetrist in conjunction with the algorithm then develops an IMRT plan that spares normal tissue. Patients with metastatic disease and previous RT commonly receive a range of doses from 30 to 66 Gy/10 to 33 fractions.

Advertisement

Of the five patients in the report, four patients experienced a complete or near complete response at three months. Two had received concurrent hyperthermia during IMRT. All experienced grade 3 dermatitis.

“These patients can be very ill, and of the five we treated, three have since passed away,” says Dr. Shah. “But our efforts to alleviate their pain and improve their quality of life by reducing their burden of cutaneous metastases are an important part of what we do here. Patients with severe cancer recurrences can have improved quality of life with the proper planning and techniques.”

Related Articles

22-CNR-3127708-CQD-Hero2-650×450-credits
November 22, 2023/Cancer/Radiation Oncology
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023/Cancer/Radiation Oncology
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

ASTRO 2022 abstracts
November 4, 2022/Cancer/Radiation Oncology
Top Research from ASTRO 2022

Key abstracts highlight advances in treating locally advanced and refractory disease

radiation therapy
October 14, 2022/Cancer/Radiation Oncology
Radiation Oncology-Biology Integration Network (ROBIN) Explores Precision Medicine

Multidisciplinary team to examine radiation therapy combined with immunotherapy

21-CNR-2572058-CQD-Hero-650×450-1
March 17, 2022/Cancer/Radiation Oncology
Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

Squamous Cell carcinoma under microscopy
December 2, 2021/Cancer/Radiation Oncology
Study Identifies Prognostic Subgroups in Cutaneous Squamous Cell Carcinoma

Modification of traditional staging factors associated with survival in high-risk disease

Ad